Low-Dose MRI-Compatible Molecular Breast Imaging Device

Information

  • Research Project
  • 8525076
  • ApplicationId
    8525076
  • Core Project Number
    R44CA144079
  • Full Project Number
    2R44CA144079-02
  • Serial Number
    144079
  • FOA Number
    PA-12-088
  • Sub Project Id
  • Project Start Date
    6/1/2010 - 13 years ago
  • Project End Date
    5/31/2016 - 7 years ago
  • Program Officer Name
    EVANS, GREGORY
  • Budget Start Date
    6/1/2013 - 10 years ago
  • Budget End Date
    5/31/2014 - 9 years ago
  • Fiscal Year
    2013
  • Support Year
    02
  • Suffix
  • Award Notice Date
    6/1/2013 - 10 years ago

Low-Dose MRI-Compatible Molecular Breast Imaging Device

DESCRIPTION (provided by applicant): Contrast-enhanced MRI has been proven to be a very sensitive modality for the early diagnosis of breast cancer in young women and/or in women with radiographically-dense breasts. The American Cancer Society recommends that high-risk women with lifetime risk greater than 20% should receive annual breast MRI screening. Depending on the practitioner and study characteristics, MRI may have a high false positive rate (with specificity reported as low as 81%), which can lead to many unnecessary procedures or even over-treatment. Positron emission mammography (PEM), the breast-specific high-resolution molecular imaging system originally invented by the PI of the submitted proposal, has been demonstrated to have a high negative predictive value. Integrating a PEM system into MRI for combined imaging is therefore likely to increase diagnostic accuracy. Furthermore, the recent commercialization of PET/CT and PET/MR clinical systems has led to wide acceptance in the oncology community for combined anatomic and molecular imaging. The goal of this application is therefore to design and construct a PEM system that could be used in conjunction with an MRI scanner. The developed PEM/MRI system in this project could be used in cancer detection, in personalizing care for breast cancer patients, and in the development of new drugs for prevention and therapy.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    666250
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:666250\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    WEINBERG MEDICAL PHYSICS, LLC
  • Organization Department
  • Organization DUNS
    809594661
  • Organization City
    BETHESDA
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    208176739
  • Organization District
    UNITED STATES